Cerebrospinal Fluid Biomarkers of Alzheimer Disease
Alzheimer disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia in the elderly. Current international guidelines for the clinical diagnosis of AD consider the diagnosis to be both clinical and biological. It requires a specific clinical phenotype and a confirmed...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2025-06-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/pathID/article/viewFile/1185/pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850044109554712576 |
|---|---|
| author | Kseniya V. Nevzorova Yuliya A. Shpilyukova Аlla A. Shabalina Ekaterina Yu. Fedotova Sergey N. Illarioshkin |
| author_facet | Kseniya V. Nevzorova Yuliya A. Shpilyukova Аlla A. Shabalina Ekaterina Yu. Fedotova Sergey N. Illarioshkin |
| author_sort | Kseniya V. Nevzorova |
| collection | DOAJ |
| description | Alzheimer disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia in the elderly. Current international guidelines for the clinical diagnosis of AD consider the diagnosis to be both clinical and biological. It requires a specific clinical phenotype and a confirmed biological origin based on biomarkers of amyloid and tau pathology. In Russia, only a few research centers perform laboratory diagnosis of AD using cerebrospinal fluid (CSF) biomarkers. Better access to laboratory diagnosis of AD and wider use of CSF biomarkers in clinical practice will help to assess the true prevalence of AD in the Russian population and to select patients for targeted pathogenic therapies based on the use of monoclonal antibodies against abnormal brain proteins, which have been actively developed in recent years. This review summarizes information on the main CSF biomarkers of AD and their diagnostic and prognostic value. |
| format | Article |
| id | doaj-art-cfa1b62c5b6e4b1092247c54a68ff5ec |
| institution | DOAJ |
| issn | 2075-5473 2409-2533 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj-art-cfa1b62c5b6e4b1092247c54a68ff5ec2025-08-20T02:55:04ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332025-06-01192829110.17816/ACEN.1185735Cerebrospinal Fluid Biomarkers of Alzheimer DiseaseKseniya V. Nevzorova0https://orcid.org/0009-0000-9148-0203Yuliya A. Shpilyukova1https://orcid.org/0000-0001-7214-583XАlla A. Shabalina2https://orcid.org/0000-0001-7393-0979Ekaterina Yu. Fedotova3https://orcid.org/0000-0001-8070-7644Sergey N. Illarioshkin4https://orcid.org/0000-0002-2704-6282Russian Center of Neurology and NeurosciencesRussian Center of Neurology and NeurosciencesRussian Center of Neurology and NeurosciencesRussian Center of Neurology and NeurosciencesRussian Center of Neurology and NeurosciencesAlzheimer disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia in the elderly. Current international guidelines for the clinical diagnosis of AD consider the diagnosis to be both clinical and biological. It requires a specific clinical phenotype and a confirmed biological origin based on biomarkers of amyloid and tau pathology. In Russia, only a few research centers perform laboratory diagnosis of AD using cerebrospinal fluid (CSF) biomarkers. Better access to laboratory diagnosis of AD and wider use of CSF biomarkers in clinical practice will help to assess the true prevalence of AD in the Russian population and to select patients for targeted pathogenic therapies based on the use of monoclonal antibodies against abnormal brain proteins, which have been actively developed in recent years. This review summarizes information on the main CSF biomarkers of AD and their diagnostic and prognostic value.https://annaly-nevrologii.com/pathID/article/viewFile/1185/pdfalzheimer’s diseasedementiabiomarkers for alzheimer diseasecerebrospinal fluid biomarkers |
| spellingShingle | Kseniya V. Nevzorova Yuliya A. Shpilyukova Аlla A. Shabalina Ekaterina Yu. Fedotova Sergey N. Illarioshkin Cerebrospinal Fluid Biomarkers of Alzheimer Disease Анналы клинической и экспериментальной неврологии alzheimer’s disease dementia biomarkers for alzheimer disease cerebrospinal fluid biomarkers |
| title | Cerebrospinal Fluid Biomarkers of Alzheimer Disease |
| title_full | Cerebrospinal Fluid Biomarkers of Alzheimer Disease |
| title_fullStr | Cerebrospinal Fluid Biomarkers of Alzheimer Disease |
| title_full_unstemmed | Cerebrospinal Fluid Biomarkers of Alzheimer Disease |
| title_short | Cerebrospinal Fluid Biomarkers of Alzheimer Disease |
| title_sort | cerebrospinal fluid biomarkers of alzheimer disease |
| topic | alzheimer’s disease dementia biomarkers for alzheimer disease cerebrospinal fluid biomarkers |
| url | https://annaly-nevrologii.com/pathID/article/viewFile/1185/pdf |
| work_keys_str_mv | AT kseniyavnevzorova cerebrospinalfluidbiomarkersofalzheimerdisease AT yuliyaashpilyukova cerebrospinalfluidbiomarkersofalzheimerdisease AT allaashabalina cerebrospinalfluidbiomarkersofalzheimerdisease AT ekaterinayufedotova cerebrospinalfluidbiomarkersofalzheimerdisease AT sergeynillarioshkin cerebrospinalfluidbiomarkersofalzheimerdisease |